Takeda to Continue with ACTOS for Treatment of Type 2 Diabetes

Takeda Pharmaceuticals North America, a part of Takeda, has reiterated its commitment to ACTOS (pioglitazone HCl) and medications having ACTOS for the treatment of type 2 diabetes following suspension announcement of rosiglitazone in the US and Europe by the FDA and the European Medicines Agency (EMA). ACTOS has same use and class as other diabetes drugs but its chemical structure is unqiue having different therapeutic effects. The drug works very well with proper diet and exercise that further improve blood sugar (glucose) control in many adults suffering from the condition.

Clinical studies have been conducted since the last 11 years in over 20,000 patients worldwide, and ACTOS has shown good results without any proof of increased danger of heart attack, stroke or death. Thus, adding the company’s confidence on the consistency and positive results of ACTOS data.

Takeda’s initiatives in the field of diabetes 

• The company in 2005, completed PROactive (PROspective PioglitAzone Clinical Trial In MacroVascular Events) trial, which was undertaken to access significant CV outcomes in type 2 diabetes patients. 
• In 1999, the company introduced ACTOS commercially for treatment of type 2 diabetes.